Gene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood disease.
Hemophilia almost always strikes males and is caused by lack of a gene that makes a protein needed for blood to clot. Small cuts or bruises can be life-threatening, and many people need treatments once or more a week to prevent serious bleeding.
TRENTON, N.J. (AP) — Could there be a second life for the once-popular arthritis pill Vioxx? A startup pharmaceutical company hopes so.
Merck & Co. voluntarily pulled the blockbuster drug in 2004 amid evidence that it doubled the chances of having a heart attack or stroke.
TRENTON, N.J. (AP) — The Latest on the possible return of Vioxx (all times local):
10:30 a.m.
Could the once-popular arthritis pill Vioxx (VEYE-ochs) get a second life? A startup pharmaceutical company hopes so.
In 2004, Merck & Co. voluntarily pulled the blockbuster drug amid evidence it doubled the chances of having a heart attack or stroke.
TRENTON, N.J. (AP) — U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia.
The Food and Drug Administration on Thursday approved Hemlibra, a weekly self-injection for hemophilia A patients who have developed resistance to standard medicines for preventing bleeding episodes.
LONDON (AP) — British Prime Minister Theresa May on Tuesday ordered a public inquiry into how contaminated blood was used to treat thousands of people in the 1970s and '80s, killing at least 2,400, according to officials.
Thousands of British public health patients — many of them hemophiliacs — were infected with the HIV virus or hepatitis C through tainted blood. Authorities looked into the infections, but campaigners and lawmakers say they did not go far enough to find out what happened.
- Globe NewswireCatalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology ConferenceNovember 6, 2019 GMT
- Business WireOrthopaedic Institute for Children’s Medical Director Mauricio Silva, M.D., Speaks at Hemophilia Conference in JordanOctober 24, 2019 GMT
- Business WireEmerging Trends, Drivers and Challenges in the Hemophilia A Therapeutics Market 2019-2023 | TechnavioAugust 21, 2019 GMT
- Globe NewswireCatalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with InhibitorsJuly 8, 2019 GMT
- Globe NewswireCatalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and HaemostasisJuly 1, 2019 GMT